Angiocrine Bioscience, Inc. filed a Form D with the Securities and Exchange Commission on 2025-09-05.
Angiocrine Bioscience, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 5, 2025. The filing reports $2.10M sold. Its industry group is Biotechnology. It names Paul Finnegan (President/Chief Executive Officer), Jeffrey Port (Director), David Parkinson (Director) (SEC Form D, September 5, 2025).
Is this your company?
Sell to companies like Angiocrine Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-05 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Angiocrine Bioscience, Inc.
Free to see. No signup.
More on the people and the money behind Angiocrine Bioscience, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in September 2025, largest first.
Get an email when Angiocrine Bioscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Angiocrine Bioscience, Inc. raises, hires or launches. No email unless you switch it on.
Watch Angiocrine Bioscience, Inc. →Get the full cited report on Angiocrine Bioscience, Inc.
What the filing shows about Angiocrine Bioscience, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Angiocrine Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Angiocrine Bioscience, Inc.'s address as 11585 Sorrento Valley Rd, Ste 109, San Diego, CA 92121.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Angiocrine Bioscience, Inc. See pricing
Angiocrine Bioscience, Inc. is a registered filer with the SEC (CIK 1569052) and has filed since 2025-09-05. 1 filing is on record, the latest on 2025-09-05.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Angiocrine Bioscience, Inc.'s Form D of 2025-09-05 names Paul Finnegan, Jeffrey Port, David Parkinson and 2 more as its officers, directors or promoters.
Its new offerings report $2.10M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
On the filing as: Executive Officer, Director.
Paul Finnegan is named as President/Chief Executive Officer on the Form D that Angiocrine Bioscience, Inc. filed with the SEC on 5 September 2025, one of 5 people that filing names.
Jeffrey Port is named as Director on the Form D that Angiocrine Bioscience, Inc. filed with the SEC on 5 September 2025, one of 5 people that filing names.
David Parkinson is named as Director on the Form D that Angiocrine Bioscience, Inc. filed with the SEC on 5 September 2025, one of 5 people that filing names.
On the filing as: Executive Officer.
John Lomoro is named as Chief Financial Officer/Treasurer on the Form D that Angiocrine Bioscience, Inc. filed with the SEC on 5 September 2025, one of 5 people that filing names.
On the filing as: Executive Officer.
John Jaskowiak is named as Chief Operating Officer/Secretary on the Form D that Angiocrine Bioscience, Inc. filed with the SEC on 5 September 2025, one of 5 people that filing names.
5 people named on the filing — 3 holding an executive role and 2 as directors only.
Named as of the 2025-09-05 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Angiocrine Bioscience, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Angiocrine Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Angiocrine Bioscience, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Angiocrine Bioscience, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Angiocrine Bioscience, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Angiocrine Bioscience, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/angiocrine-bioscience-inc-form-d-25000001